Michael M. Kaminski

Michael M. Kaminski

Auto-generated profile, based on publicly available information

Michael M. Kaminski

Department of Nephrology and Medical Intensive Care, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Charitéplatz 1, 10117 Berlin, Germany

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 August 2022 in Nature Nanotechnology
Verified
Journal Article
Closed access
PDF file
MAMarta Broto Aviles
Marta Broto Aviles
MKMichael M. Kaminski
Michael M. Kaminski
CAChristopher Adrianus
Christopher Adrianus
NKNayoung Kim
Nayoung Kim
RGRobert Greensmith
Robert Greensmith
MSMolly M. Stevens
Molly M. Stevens

5 November 2021 in Development
Verified
Journal Article
Open access
PDF file
TNThomas Naert
Thomas Naert
ÖÇÖzgün Çiçek
Özgün Çiçek
POPaulina Ogar
Paulina Ogar
MBMax Bürgi
Max Bürgi
NSNikko-Ideen Shaidani
Nikko-Ideen Shaidani
SLSoeren S. Lienkamp
Soeren S. Lienkamp
Genome editing simplifies the generation of new animal models for congenital disorders. However, the detailed and unbiased phenotypic assessment of altered embryonic development remains a challenge. Here, we explore how deep learning (U-Net) can automate segmentation tasks in various imaging modalities, and we quantify phenotypes of altered renal, neural and craniofacial development in Xenopus embryos in comparison with normal variability. We demonstrate the utility of this approach in embryos with polycystic kidneys (pkd1 and pkd2) and craniofacial dysmorphia (six1). We highlight how in toto light-sheet microscopy facilitates accurate reconstruction of brain and craniofacial structures within X. tropicalis embryos upon dyrk1a and six1 loss of function or treatment with retinoic acid inhibitors. These tools increase the sensitivity and throughput of evaluating developmental malformations caused by chemical or genetic disruption. Furthermore, we provide a library of pre-trained networks and detailed instructions for applying deep learning to the reader's own datasets. We demonstrate the versatility, precision and scalability of deep neural network phenotyping on embryonic disease models. By combining light-sheet microscopy and deep learning, we provide a framework for higher-throughput characterization of embryonic model organisms. This article has an associated ‘The people behind the papers’ interview.

1 December 2023 in Science Advances
Verified
Journal Article
Open access
KIKatherine Ilia
Katherine Ilia
NSNika Shakiba
Nika Shakiba
TBTrevor Bingham
Trevor Bingham
RJRoss D. Jones
Ross D. Jones
MKMichael M. Kaminski
Michael M. Kaminski
TSThorsten M. Schlaeger
Thorsten M. Schlaeger
Reprogramming human fibroblasts to induced pluripotent stem cells (iPSCs) is inefficient, with heterogeneity among transcription factor (TF) trajectories driving divergent cell states. Nevertheless, the impact of TF dynamics on reprogramming efficiency remains uncharted. We develop a system that accurately reports OCT4 protein levels in live cells and use it to reveal the trajectories of OCT4 in successful reprogramming. Our system comprises a synthetic genetic circuit that leverages noise to generate a wide range of OCT4 trajectories and a microRNA targeting endogenous OCT4 to set total cellular OCT4 protein levels. By fusing OCT4 to a fluorescent protein, we are able to track OCT4 trajectories with clonal resolution via live-cell imaging. We discover that a supraphysiological, stable OCT4 level is required, but not sufficient, for efficient iPSC colony formation. Our synthetic genetic circuit design and high-throughput live-imaging pipeline are generalizable for investigating TF dynamics for other cell fate programming applications.

21 August 2025 in Molecular Therapy
Verified
Journal Article
Open access
AIAntonia Ibel
Antonia Ibel
RBRishi Bhardwaj
Rishi Bhardwaj
DYDuygu Elif Yilmaz
Duygu Elif Yilmaz
SKShuhan Kong
Shuhan Kong
SWSarah Wendlinger
Sarah Wendlinger
MKMichael M. Kaminski
Michael M. Kaminski
Autosomal dominant polycystic kidney disease (ADPKD) is the most prevalent genetic kidney disorder, affecting over 10 million individuals worldwide. Cystic expansion typically progresses to kidney failure and also involves the liver with limited treatment options. Pathogenic variants in PKD1 or PKD2 account for 85-90% of cases. Genetic re-expression of Pkd1 or Pkd2 has been shown to partially reverse key characteristics of the disease phenotype in mice. Despite advancements in understanding the genetic basis, it remains unclear whether correcting pathogenic variants can effectively prevent, modify, or reverse the disease. Additionally, the feasibility of genome editing as a treatment remains largely unexplored. In this study, we employed CRISPR base editing to correct representative pathogenic PKD1 variants selected from a patient cohort, achieving precise and efficient editing in vitro. Correction of a murine missense variant (c.6646C>T (R2216W)) in primary renal epithelial cells increased polycystin-1 expression and reduced the endoplasmic reticulum stress marker sXBP1. In vivo, base editor delivery to the c.6646C>T (R2216W) knock-in mouse enabled correction of the pathogenic variant, resulting in a significant reduction in liver cysts. These findings provide the first evidence that genome editing may ameliorate key features of ADPKD, opening promising therapeutic perspectives for affected patients and their families.

13 September 2024 in EMBO Molecular Medicine
Verified
Journal Article
Open access
RGRobert Greensmith
Robert Greensmith
ILIsadora T Lape
Isadora T Lape
CRCristian V Riella
Cristian V Riella
ASAlexander J Schubert
Alexander J Schubert
JMJakob J Metzger
Jakob J Metzger
MKMichael M Kaminski
Michael M Kaminski
Detecting genetic variants enables risk factor identification, disease screening, and initiation of preventative therapeutics. However, current methods, relying on hybridization or sequencing, are unsuitable for point-of-care settings. In contrast, CRISPR-based-diagnostics offer high sensitivity and specificity for point-of-care applications. While these methods have predominantly been used for pathogen sensing, their utilization for genotyping is limited. Here, we report a multiplexed CRISPR-based genotyping assay using LwaCas13a, PsmCas13b, and LbaCas12a, enabling the simultaneous detection of six genotypes. We applied this assay to identify genetic variants in the APOL1 gene prevalent among African Americans, which are associated with an 8–30-fold increase in the risk of developing kidney disease. Machine learning facilitated robust analysis across a multicenter clinical cohort of more than 100 patients, accurately identifying their genotypes. In addition, we optimized the readout using a multi-analyte lateral-flow assay demonstrating the ability for simplified genotype determination of clinical samples. Our CRISPR-based genotyping assay enables cost-effective point-of-care genetic variant detection due to its simplicity, versatility, and fast readout.

11 September 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
ANAna-Maria Nitulescu
Ana-Maria Nitulescu
WDWeijie Du
Weijie Du
VGViktor Glaser
Viktor Glaser
JKJonas Kath
Jonas Kath
RGRobert Greensmith
Robert Greensmith
DWDimitrios L. Wagner
Dimitrios L. Wagner
Non-viral gene editing via CRISPR-Cas12a offers an alternative to Cas9-based methods, providing better targeting of AT-rich regions, simplified guide RNA manufacturing, and high specificity. However, the efficacy of editing outcomes is subject to various factors, with template format playing a crucial role. Currently, the predominant non-viral template format for inducing homology-directed repair (HDR) after nuclease-induced DNA breaks is double-stranded DNA (dsDNA), which is toxic when transfected at high doses. Previous studies have demonstrated that using single-stranded DNA (ssDNA) with flanking double-stranded Cas-target-sequences (CTS) as a repair template for Cas9-mediated gene editing can mitigate this toxicity and increase knock-in efficiency. Here, we investigate CTS design for AsCas12a Ultra by exploring PAM orientation and binding requirements of the Cas12a-crRNA complex. Additionally, we rule out in vitro ssDNase activity of AsCas12a Ultra under cell-physiological Mg 2+ conditions. Finally, we showcase the advantage of using ssDNA with double-stranded CTS end modifications (ssCTS) at high doses for delivering clinically relevant transgenes of varying sizes into three T-cell receptor-CD3 complex genes ( TRAC , CD3 ζ , CD3 ε), achieving up to 90% knock-in rates for a 0.8kb insert at the CD3 ε locus. Overall, AsCas12a Ultra and ssCTS donors represent a platform for highly efficient knock-in in primary human T cells with minimal toxicity.